Scarica l'app Stockscreener
19.62
4.64%
-0.955
Dopo l'orario di chiusura:
19.80
0.175
+0.89%
Precedente Chiudi:
$20.58
Aprire:
$20.82
Volume 24 ore:
172.01K
Relative Volume:
0.57
Capitalizzazione di mercato:
$796.17M
Reddito:
-
Utile/perdita netta:
$-136.98M
Rapporto P/E:
-4.8818
EPS:
-4.02
Flusso di cassa netto:
$-126.63M
1 W Prestazione:
-7.12%
1M Prestazione:
+7.83%
6M Prestazione:
+9.64%
1 anno Prestazione:
-34.01%
Intervallo 1D:
$19.33
$21.00
Intervallo di 1 settimana:
$19.33
$21.32
Portata 52W:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
19.62 | 811.38M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-03-20 | Iniziato | B. Riley Securities | Buy |
| 2025-03-10 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Mostra tutto
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
What’s the recovery path for long term holders of ArriVent BioPharma Inc.Trade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
ArriVent BioPharma (NASDAQ:AVBP) Cut to Strong Sell at Zacks Research - Defense World
Why ArriVent BioPharma Inc. stock is favored by pension fundsQuarterly Profit Report & Real-Time Stock Movement Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with multi timeframe charts2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Is ArriVent BioPharma The Next Big Player In Targeted Cancer Therapies? - RTTNews
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com
Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com
How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN
Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com
Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com
ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria
ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz
ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks
Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):